| Protocol No. | PI | Title |
|---|
| OSU-11017 | Ronney Abaza | A Pilot Clinical Trial for the Prevention of Postoperative Lymphoceles Using Absorbable Micorporous Polysaccharide Hemosphere Particles during Robotic Assisted Prostatectomy with Lymph Node Dissection |
| OSU-05127 | Doreen Agnese | A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patient with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. |
| CALGB-100701 | Leslie Andritsos | Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) |
| CALGB-20802 | Leslie Andritsos | Embedded Protocol to CALGB-100701 |
| OSU-11170 | Robert Bahnson | A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols |
| CALGB-71003 | Tony Bekaii-Saab | Embedded Companion to CALGB-80803 |
| CALGB-151007 | Tony Bekaii-Saab | Embedded Companion to CALGB-80803 |
| CALGB-80803 | Tony Bekaii-Saab | RANDOMIZED PHASE II TRIAL OF PET SCAN-DIRECTED COMBINED MODALITY THERAPY IN
ESOPHAGEAL CANCER
|
| OSU-11147 | Tony Bekaii-Saab | A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer |
| SWOG-S1201 | Tony Bekaii-Saab | "A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer |
| OSU-12136 | Tony Bekaii-Saab | NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 versus 5- Fluorouracil and Leucovorin versus 5-Flourouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer Who have Failed Prior Gemcitabine-based Therapy |
| CALGB-580901 | Tony Bekaii-Saab | Embedded Companion to CALGB 80802 |
| CALGB-150902 | Tony Bekaii-Saab | Embedded Companion to CALGB 80802 |
| CALGB-60901 | Tony Bekaii-Saab | Embedded Companion Study to CALGB 80802 |
| OSU-10045 | Tony Bekaii-Saab | A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel plus Reovirus Serotype-3 Dearing Strain (Reolysin®) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients with Recurrent or Metastatic Pancreatic Cancer |
| CALGB-80802 | Tony Bekaii-Saab | A Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib Alone In Patients with Advanced Hepatocellular Carcinoma (HCC). |
| CALGB-580601 | Tony Bekaii-Saab | Embedded companion to CALGB 80302: |
| CALGB-60601 | Tony Bekaii-Saab | Embedded Companion to CALGB 80403: Pharmacogenomic companion in CALGB 80403. |
| CALGB-70502 | Tony Bekaii-Saab | Embedded Companion Study to CALGB 80405 |
| CALGB-150506 | Tony Bekaii-Saab | Embedded Companion Study to CALGB 80405 |
| CALGB-60501 | Tony Bekaii-Saab | Embedded Companion to CALGB 80405 |
| OSU-08078 | Tony Bekaii-Saab | A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumor in first line medical treatment |
| OSU-10029 | Don Benson, Jr | An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies |
| OSU-08191 | Don Benson, Jr | Immunologic Studies in Hematological Malignancies: Mechanisms of Action in Natural Killer Cell Targeting of Acute Leukemias |
| OSU-11102 | Don Benson, Jr | A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma |
| OSU-12117 | Erin Bertino | A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) |
| OSU-10112 | Erin Bertino | Enhancement of Cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with Lenalidomide in Advanced Solid Tumors: A Phase I/IB study |
| OSU-12099 | Arvinder Bhinder | A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
|
| OSU-12100 | Arvinder Bhinder | A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration- resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 |
| OSU-11083 | Arvinder Bhinder | A Randomized Controlled Study of YONDELIS¿¥ (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide |
| CALGB-60202 | Clara Bloomfield | Embedded companion to CALGB 40101: Drug Metabolism and Transport PG in Breast CA patients on CALGB 40101 |
| OSU-11113 | P. Mark Bloomston | A Randomized Prospective Multicenter Trial of Pancreas Resection with and without Routine Intraperitoneal Drainage
|
| OSU-11157 | P. Mark Bloomston | A Phase 1/2a Dose-escalation Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Followed by Intratumoral (IT) Boosts Alone and in Combination with Irinotecan in Patients with Metastatic, Refractory Colorectal Carcinoma |
| OSU-12017 | Kristie Blum | A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patinets with Relapse or Refractory Diffuse Large B-CellLymphoma (DLBCL) |
| SWOG-S1106 | Kristie Blum | A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients Less than or Equal to 65 Years of Age with Previously Untreated Mantle Cell Lymphoma |
| OSU-11077 | Kristie Blum | An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma |
| OSU-11015 | Kristie Blum | A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
|
| CALGB-151005 | Kristie Blum | Embedded Companion to CALGB-50904 |
| ECOG-E1411 | Kristie Blum | Intergroup Randomized Phase II Four Arm Study In Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-> LR) |
| OSU-12106 | Kristie Blum | A PHASE II STUDY OF MLN8237 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| CALGB-50303 | Kristie Blum | Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas |
| CALGB-60405 | Kristie Blum | Embedded companion to CALGB 50303: Pharmacogenomics in CALGB 50303. |
| CALGB-580603 | Kristie Blum | Embedded Companion to CALGB-50303: Evaluating the Prognostic Utility of PET Scanning in Lymphoma |
| OSU-10049 | Kristie Blum | A Phase II trial of panobinostat and lenalidomide in patients with relasped or refractory Hodgkins's Lymphoma |
| OSU-10052 | Kristie Blum | A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination with Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients with Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent non-Hodgkin's lymphoma |
| CALGB-50801 | Kristie Blum | Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma |
| CALGB-150805 | Kristie Blum | Embedded Companion Study to CALGB-50604 |
| CALGB-150903 | Kristie Blum | Embedded Companion study to CALGB-50801 |
| CALGB-150913 | Kristie Blum | Embedded companion to CALGB-50803 |
| CALGB-50904 | Kristie Blum | RANDOMIZED PHASE II TRIAL OF OFATUMUMAB AND BENDAMUSTINE VS. OFATUMUMAB, BORTEZOMIB (NSC #681239, IND #58443) AND BENDAMUSTINE IN PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA |
| OSU-10016 | William Blum | Phase I Study of Lenalidomide and Conventional Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia |
| CALGB-20703 | William Blum | Embedded Companion Study to CALGB-10502 |
| SWOG-S0535 | William Blum | Phase II study of ATRA, Arsenic Trioxide and Gematuzumab Ozogamicin in pts with previously untreated high risk APL. |
| CALGB-60604 | William Blum | Embedded companion to CALGB 10503: Busulfan PK in 10503 |
| CALGB-20602 | William Blum | Embedded companion to CALGB 10503;Correlative science in CALGB 10503 |
| OSU-05024 | Roger Briesewitz | Effect of Small Molecule Kinase Inhibitors on the Proliferation and Survival of Primary AML Cells Ex Vivo. |
| CALGB-20203 | John Byrd | Molecular Markers of Chronic Lymphocytic Leukemia. |
| OSU-0017 | John Byrd | Chronic Lymphocytic Leukemia Research Consortium Human Subjects Protocol for Sample Collection |
| OSU-05099 | John Byrd | Normal Spleen and Tonsil Tissue for Research Use. |
| OSU-05128 | John Byrd | Use of Red Cross Leukopacs as Source of Normal Human Cells for Research Use. |
| CALGB-70603 | John Byrd | Embedded Campanion Study to CALGB-10501 |
| CALGB-20601 | John Byrd | Embeded Companion Study to CALGB-10501 |
| CALGB-20702 | John Byrd | Embeded Campion Study to CALGB-10404 |
| OSU-12024 | John Byrd | A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| OSU-12062 | John Byrd | A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies |
| OSU-11176 | John Byrd | A Long-Term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia |
| OSU-11166 | William Carson | A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors |
| OSU-11117 | Spero Cataland | A Multicenter, Open-label Study to Compare on-Demand Treatment to a Prophylaxis Regimen of Nonacog-alfa (benefix) in Subjects with Moderately Severe to Severe Hemophilia B |
| OSU-05049 | Spero Cataland | Concurrent Cyclosporine and Plasma Exchange Therapy as Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP) |
| OSU-05050 | Spero Cataland | Standardized Therapy of Thrombotic Thrombocytopenic Purpura |
| ECOG-E3F05 | Robert Cavaliere | Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas |
| RTOG-0929 | Robert Cavaliere | A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma. |
| OSU-13094 | Robert Cavaliere | HSPPC-96 Expanded Access (Compassionate Use) Treatment Protocol for an individual Patient |
| CALGB-150910 | Beth Christian | Embedded Companion to CALGB-50901 |
| CALGB-50901 | Beth Christian | A PHASE II TRIAL OF OFATUMUMAB (CALGB IND# 112390) IN PREVIOUSLY UNTREATED FOLLICULAR NON-HODGKIN¿S LYMPHOMA (NHL) |
| CALGB-150403 | Steven Clinton | Embedded companion to CALGB 90202: N-telopeptide as a prognostic marker for PCa patients on 90202 |
| OSU-09127 | David Cohn | A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma. |
| OSU-12241 | David Cohn | Compassionate Use Protocol : International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
|
| OSU-05041 | Albert de la Chapelle | Genetic Ancestry and its Implications in Cytogenetic and Molecular Abnormalities of Acute Myeloid Leukemia. |
| OSU-0241 | Steve Devine | Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation (A National Marrow Donor Program Protocol). |
| OSU-0242 | Steve Devine | A Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (A National Marrow Donor Program Protocol). |
| CALGB-60402 | Steve Devine | Embedded companion to CALGB 100103: Busulfan Pharmacokinetics in Elderly Leukemic Patients in CALGB 100103 |
| CALGB-100801 | Steve Devine | Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML |
| CALGB-151001 | Steve Devine | Embedded Companion Study to CALGB-100801 |
| OSU-11087 | Steve Devine | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications |
| RTOG-1008 | Virginia Diavolitsis | A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
|
| RTOG-0813 | Virginia Diavolitsis | Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients. |
| OSU-09088 | Yvonne Efebera | A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma |
| OSU-11052 | Yvonne Efebera | A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) |
| OSU-11004 | Yvonne Efebera | Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease(GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT) |
| OSU-11088 | Yvonne Efebera | Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft versus Host Disease
|
| OSU-11032 | Eric Eisenhauer | A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors |
| OSU-12133 | Eric Eisenhauer | A Phase I, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients with Advanced Solid Malignancies |
| OSU-12105 | James Elder | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 |
| NSABP-B-47 | William Farrar | Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| NSABP-B-43 | William Farrar | A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. |
| RTOG-0920 | Maura Gillison | A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer |
| OSU-09074 | Maura Gillison | Phase I/II study of dasatinib, cetuximab and radiation with or without cisplatin in locally advanced squamous cell carcinoma of head and neck (HNSCC) |
| RTOG-1016 | Maura Gillison | PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER |
| OSU-11124 | Maura Gillison | Randomized Double-Blind Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) |
| RTOG-3501 | Maura Gillison | TRYHARD: A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF LAPATINIB (TYKERB®) FOR NON-HPV LOCALLY ADVANCED HEAD AND NECK CANCER WITH CONCURRENT CHEMORADIATION. |
| OSU-11182 | Richard Goldberg | A Phase II Study of the Combination of Aflibercept (VEGF-Trap) plus Modified FOLFOX 6 in Patients with Previously Untreated Metastatic Colorectal Cancer |
| OSU-12033 | Gayle Gordillo | MASTECTOMY RECONSTRUCTION OUTCOMES CONSORTIUM (MROC) STUDY |
| OSU-08142 | John Grecula | Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients with 1- 4 Brain Metastases from Solid Malignancies |
| CALGB-30610 | John Grecula | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide |
| OSU-08111 | John Grecula | MR-Predictive-Assay in Pre-Operative Lung Cancer Therapy: Response/Resectability |
| CALGB-150712 | John Grecula | Embedded Companion Study to CALGB 30610 |
| CALGB-70702 | John Grecula | Embedded Companion to CALGB 30610 |
| OSU-07012 | Craig Hofmeister | Retrospective Case-Control Study of the Effect of Statin use on Clinical Response to Autologous Stem Cell Transplantation in Myeloma Patients. |
| OSU-09102 | Craig Hofmeister | A Phase I Study of AR-42 in Adult Patients with Advanced or Recurrent Hematologic Malignancies and Solid Tumors, for Which No Standard Therapy is Available |
| OSU-11159 | Craig Hofmeister | A PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) FOR THE COMBINATION OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| OSU-11048 | Craig Hofmeister | A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies |
| OSU-11163 | Samantha Jaglowski | A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| OSU-06061 | Sonata Jodele | Expanded Access Protocol for Purging of Peripheral Blood Stem Cells or Bone Marrow from Patients with High Risk Neuroblastoma Prior to Autologous Transplantation Under FDA Investigational Device Exemption BB-IDE-2259 |
| CALGB-150711 | Jeffrey Jones | Embedded Campanion Study to CALGB-50701 |
| OSU-10001 | Jeffrey Jones | Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol at a Comprehensive Cancer Center |
| OSU-10156 | Jeffrey Jones | Phase II study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features |
| OSU-12200 | Jeffrey Jones | A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia |
| OSU-11120 | Jeffrey Jones | Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL |
| OSU-12123 | Jeffrey Jones | A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia |
| OSU-12142 | Jeffrey Jones | A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
| OSU-11024 | Kari Kendra | BRF114144: A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumor |
| OSU-10036 | Hooman Khabiri | A Humanitarian Device Exemption Treatment Protcol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma |
| OSU-09027 | Edward Kim | Use of PET-CT in Neoadjuvant Chemoradiation Therapy for Stage IIIA NSCLC |
| OSU-07068 | Rebecca Klisovic | Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD |
| OSU-07069 | Rebecca Klisovic | Myeloproliferative Disorder Research Consortium (MPD-RC) Research Tissue Bank |
| OSU-12163 | Rebecca Klisovic | A Phase IIa, Single-Arm,Open-Label Study of MOR00208,a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL).
|
| OSU-07042 | Michael Knopp | Imaging of the Prostate Gland Using High Field Strength 3T MRI |
| OSU-0361 | Michael Knopp | Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit. |
| OSU-08063 | Michael Knopp | Imaging of the Bladder Tumor Using Clinical 3 Tesla MRI and Ex-Vivo Ultra-high-field MRI |
| CALGB-70701 | Kavitha Kosuri | Embedded Companion Study to CALGB-30607 |
| CALGB-60702 | Kavitha Kosuri | Embedded Companion Study to CALGB-30607 |
| CALGB-150707 | Kavitha Kosuri | Embedded Substudy "A Phase II Study of Dasatinib (NSC # 732517) in Patient w/ Previously Treated Malignant Mesothelioma" |
| CALGB-150704 | Kavitha Kosuri | Embedded Companion Study to CALGB-30605 |
| OSU-0384 | Eric Kraut | Universal Data and Serum Specimen Collection System for Hemophilia |
| OSU-05021 | Eric Kraut | Epidemiology and Treatment of Circulating Anticoagulants in Patients with Hemophilia and VonWillebrand's Disease - The HTRS Registry |
| OSU-06020 | Eric Kraut | An Evaluation of Qualitative Platelet Disorders in Patients with Inherited Disorders of Coagulation. |
| OSU-05094 | Sean Lawler | Investigating Novel Therapeutic Strategies for Brain Tumor Treatment. |
| CALGB-150714 | Rachel Layman | Embedded Companion Study to CALGB-40502 |
| CALGB-60704 | Rachel Layman | Embedded Companion Study to CALGB-40502 |
| OSU-0025 | David Lucas | Drug Sensitivity & Apoptosis Studies in Hematologic Malignancies |
| OSU-08140 | Maryam Lustberg | Isolation and Characterization of Circulating Tumor Cells in Localized and Metastatic Breast Cancer Patients by Immunocytochemical and PCR Detection after Immunomagnetic Cell Enrichment |
| OSU-12127 | Maryam Lustberg | A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation |
| OSU-11022 | Maryam Lustberg | Prevention of Aromatase Inhibitor-Induced Joint Symptoms with Omega 3 Fatty Acid Supplementation: a randomized placebo controlled pilot study |
| SWOG-S1007 | Maryam Lustberg | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less |
| OSU-11133 | Kami Maddocks | A Phase 2 Study of the Bruton¿s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Genetic Risk-Stratified Relapsed and Refractory Patients with Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL) |
| OSU-11162 | Kami Maddocks | A Pilot Two-Step Phase II Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Lymphoma (PLL) |
| OSU-11179 | Kami Maddocks | A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin¢¯s Lymphoma |
| OSU-12095 | Kami Maddocks | A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia |
| CALGB-211006 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-361006 | Guido Marcucci | Embedded Companion to CALGB-11001 |
| CALGB-21003 | Guido Marcucci | Embedded Companion to CALGB-11001 |
| CALGB-21101 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-361101 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-11001 | Guido Marcucci | A PHASE II STUDY INCORPORATING SORAFENIB (IND 69896, NSC 724772) INTO THE THERAPY OF PATIENTS ¡Ý 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA
|
| CALGB-60706 | Guido Marcucci | Embeded Campanion Study to CALGB 10603 |
| CALGB-20502 | Guido Marcucci | Molecular Genetic Studies of Acute Myeloid Leukemia (AML) with Normal Cytogenetics: A CALGB Leukemia Tissue Bank Project |
| CALGB-20202 | Guido Marcucci | Assessment of Novel Molecular Markers in Acute Myeloid Leukemia |
| RTOG-0534 | Douglas Martin | A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy |
| RTOG-1115 | Douglas Martin | Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer |
| OSU-10055 | Joel Mayerson | Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology |
| RTOG-0724 | Nina Mayr | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy. |
| OSU-08141 | Nina Mayr | MRI-Predictive Assay of Treatment Outcome in Cancer of the Cervix |
| OSU-08118 | Ehud Mendel | Functional Outcome in Patients Following Surgical Decompression and Stabilization for Spinal Metastases: Surgical Impact and Quality of Life |
| CALGB-90203 | J. Paul Monk | A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer |
| CALGB-150413 | J. Paul Monk | Embedded companion to CALGB 90203: |
| CALGB-150412 | J. Paul Monk | Embedded companion to CALGB 90203: |
| OSU-11116 | J. Paul Monk | A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer |
| OSU-11151 | J. Paul Monk | Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma |
| OSU-11132 | J. Paul Monk | A Randomized, Double-Blind, Placebo-Controlled Phase II study of ARQ 197 (tivantinib) in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer. |
| CALGB-60701 | Ewa Mrozek | Embedded Companion to CALGB-40601
|
| CALGB-150702 | Ewa Mrozek | Embedded Companion to CALGB-40601 |
| OSU-12094 | Herbert Newton | A Prospective, Multi-center Trial of NovoT T F-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM |
| OSU-12079 | Herbert Newton | An International, Randomized, Double-Blind, Controlled Study of
Rindopepimut/GMCSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma |
| OSU-08028 | Ryan Niederkohr | Retrospective Evaluation of the Accuracy of PET/CT with Respect to Surgiscal Planning in Patients with Colorectal Cancer |
| OSU-08113 | Ryan Niederkohr | Retrospective Evaluation of the Prognostic Value of Total Tumor Volume Versus SUV in Patients with Lung Cancer Undergoing FDG PET/CT |
| GOG-213 | David O'Malley | Phase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel in Combination w/ Bevacizumab followed by Bevacizumab & Secondary Cytoreductive Surgery in Platinum-sensitive Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer |
| GOG-212 | David O'Malley | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) versus no Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum / Taxane Chemotherapy. |
| OSU-09115 | David O'Malley | Phase I Study of Intraperitoneal Carboplatin with Intravenous Paclitaxel and Bevacizumab in Patients with Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma |
| GOG-9923 | David O'Malley | A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab [NSC #704865, IND #7921] and CTEP-Supplied Agent ABT-888 [NSC #737664, IND #77840] in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| GOG-0264 | David O'Malley | A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary |
| GOG-0262 | David O'Malley | Randomized Phase III trial of every 3 weeks Paclitaxel versus dose dense weekly Paclitaxel in combination with Carboplatin with or without concurrent and consolidation Bevacizumab (NSC# 704865, IND #7921) in the treatment of primary stage III or IVE Epithelial Ovarian, Peritoneal or Fallopian |
| GOG-0186H | David O'Malley | A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN® NSC # 729968, BB-IND # 13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER |
| GOG-0268 | David O'Malley | A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied agent: NCS# 683864, IND # 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Concolidation as First Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary |
| GOG-0277 | David O'Malley | A PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE LEIOMYOSARCOMA |
| OSU-12038 | David O'Malley | Randomized Phase II Evaluation of Carboplatinipaclitaxel with and
without Trastuzumab (Herceptin®) in Her2/Neu+ Patients with
Advancedirecurrent Uterine Serous Papillary Carcinoma
|
| GOG-0275 | David O'Malley | A PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA |
| GOG-3003 | David O'Malley | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF VTX-2337 (IND #78,416) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER |
| GOG-3001 | David O'Malley | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers |
| GOG-0241 | David O'Malley | Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (Meoc) |
| GOG-0076HH | David O'Malley | A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and Ctep Supplied Agent Abt-888 (Velaparib) (Ind#77840, Nsc#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix |
| GOG-0274 | David O'Malley | A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL |
| GOG-0229L | David O'Malley | A PHASE II TRIAL OF AMG 386 (IND#111071), A SELECTIVE ANGIOPOIETIN 1/2 NEUTRALIZING PEPTIBODY, IN PATIENTS WITH PERSISTENT/RECURRENT CARCINOMA OF THE ENDOMETRIUM |
| GOG-9927 | David O'Malley | A PHASE I TRIAL OF DOXIL®, CARBOPLATIN AND NCI SUPPLIED VELIPARIB (ABT-888) IN RECURRENT PLATINUM SENSITIVE OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER |
| OSU-12155 | Thomas Olencki | A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy |
| OSU-12061 | Erin Olson | A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive advanced (metastatic or locally advanced) breast cancer |
| ECOG-E5508 | Greg Otterson | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| CALGB-30801 | Greg Otterson | A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer |
| CALGB-30901 | Greg Otterson | Randomized phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy |
| CALGB-150912 | Greg Otterson | Embedded Companion Study to CALGB-30901 |
| CALGB-580903 | Greg Otterson | Embedded Companion Study to CALGB-30901 |
| CALGB-150908 | Greg Otterson | Embedded Protocol to CALGB-30801 |
| CALGB-60904 | Greg Otterson | Embedded Companion Studu to CALGB-30801 |
| CALGB-150701 | Greg Otterson | Embedded Companion Study to CALGB-30504 |
| CALGB-60705 | Greg Otterson | Embedded Companion Study to CALGB 30704 |
| CALGB-580702 | Greg Otterson | Embedded Campanion Study to CALGB 30704 |
| OSU-07061 | Enver Ozer | A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System. |
| RTOG-0631 | Christopher Pelloski | Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis |
| OSU-12002 | Mitch Phelps | A PROSPECTIVE, DOUBLE-BLINDED, OBSERVATIONAL CLINICAL COHORT STUDY OF THE ASSOCIATION BETWEEN TACROLIMUS EXPOSURE AND CYP3A4, CYP3A5 GENOTYPES IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS |
| SWOG-S1011 | Kamal Pohar | A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at time of Radical Cystectomy for Muscle Invasive Urothelial Cancer |
| OSU-12160 | Pierluigi Porcu | A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies |
| OSU-09073 | Pierluigi Porcu | Computer-aided Clinical Image Analysis for Cutaneous Lymphomas |
| OSU-05075 | Pierluigi Porcu | A Retrospective Analysis of Clinical Presentation and Therapeutic Outcomes in T/NK-cell Lymphomas at the OSUCCC as a Benchmark for Future Translational Studies, Clinical Trial Design and Prediction of Accrual. |
| OSU-10025 | Stephen Povoski | Restrospective Evaluation of Patients Undergoing Surgery and Same-Day Intravenous Administration of 18F-FDG |
| ECOG-E2108 | Stephen Povoski | A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
|
| RTOG-1119 | Allison Quick | PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER A COLLABORATIVE STUDY OF RTOG AND KROG |
| CALGB-150804 | Bhuvaneswari Ramaswamy | Embedded companion study to CALGB 70604 |
| CALGB-60803 | Bhuvaneswari Ramaswamy | Embedded companion study to CALGB 70604 |
| OSU-10097 | Bhuvaneswari Ramaswamy | A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastic Breast Cancer |
| CALGB-150605 | Bhuvaneswari Ramaswamy | Embedded Companion Study to CALGB-40503 |
| CALGB-60605 | Bhuvaneswari Ramaswamy | Embedded Companion Study to CALGB-40503 |
| CALGB-140503 | Patrick Ross | A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small < 2cm Peripheral Non-Small Cell Lung Cancer |
| ECOG-1505 | Patrick Ross | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) |
| OSU-12072 | Patrick Ross | Photodynamic Therapy (PDT) Oncology Registry |
| SLE-05001 | Brad Rovin | A Phase III, randomized, double-blind placebo-controlled, multicenter study to evaluate the efficacy and safety of retiximab in subjects with ISN/PRS class III or IV lupus nephritis |
| OSU-12037 | Ritu Salani | A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patients with Platinum Resistant/ Refractory Advanced Ovarian Cancers |
| ECOG-E1305 | Panayiotis Savvides | A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer |
| ECOG-1208 | Carl Schmidt | A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HHC) in Patients with and without Vascular Invasion |
| NCCTG-N1048 | Carl Schmidt | A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision. |
| OSU-11084 | Ahmad Shabsigh | Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial |
| OSU-12064 | Manisha Shah | A Randomized Phase 2 Study of single agent GSK2118436 (BRAFi) vs combination regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in patients with BRAF mutated thyroid carcinoma |
| OSU-12066 | Manisha Shah | A Phase I trial of GSK2118436 (BRAFi) and Pazopanib in patients with BRAF-mutated advanced malignant tumors |
| OSU-12154 | Manisha Shah | Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy |
| OSU-12153 | Manisha Shah | A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC)versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after
failure of mTOR inhibitor therapy. |
| OSU-12111 | Charles Shapiro | A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer |
| OSU-12112 | Charles Shapiro | A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON) |
| OSU-10117 | David Sharp | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy. |
| OSU-09120 | Ted Teknos | A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nasopharyngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck.
|
| OSU-12055 | Alicia Terando | Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma |
| OSU-06112 | Amanda Termuhlen | Dose Intensive Chemotherapy for Children Less than Ten Years of Age Newly-Diagnosed with Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation with Myeloablative Chemotherapy (Thiotepa and Carboplatin, with or without Etoposide) and Autologous Stem Cell Rescue. |
| OSU-11066 | Sumithira Vasu | KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor |
| OSU-12167 | Miguel Villalona | A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations. |
| OSU-07082 | Miguel Villalona | Analysis of FANCD2 Protein Monoubiquitin Status and Nuclear Foci Formation in the Primary Solid Tumors |
| OSU-09100 | Miguel Villalona | ABT-888 as monotherapy and in combination with Mitomycin C in patients with solid tumors with deficiency in homologous recombination repair. |
| OSU-10152 | Miguel Villalona | Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available |
| OSU-09111 | Alison Walker | Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia |
| OSU-11021 | Alison Walker | Research database for undiagnosed cytopenias. |
| OSU-12234 | Katherine Walsh | Randomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) (A New York Cancer Consortium Study) |
| OSU-11013 | Katherine Walsh | A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) |
| OSU-07151 | Harrison Weed | Preoperative Alcohol Use and Postoperative Complications of Major Head and Neck Cancer Surgery
|
| OSU-06045 | Brian Weiss | A Compassionate Use Protocol Using I-Metaiodobenzylguandine (131 I-MIBG)Therapy in Patients with Refractory Neuroblastoma. |
| OSU-12187 | Robert Wesolowski | Single-Patient Compassionate Use Treatment using Trastuzumab Emtansine (T-DM1) For Her2-Positive Metastatic Breast Cancer |
| OSU-12078 | Robert Wesolowski | THE BEACON STUDY (BREAST CANCER OUTCOMES WITH NKTR-102):A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN¿S CHOICE (TPC) IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A AXANE, AND CAPECITABINE |
| CALGB-150709 | Robert Wesolowski | Embedded Companion to CALGB-40603 |
| CALGB-60703 | Robert Wesolowski | Embedded Companion to CALGB-40603 |
| OSU-12018 | Robert Wesolowski | A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors |
| RTOG-1005 | Julia White | A PHASE III TRIAL OF ACCELERATED WHOLE BREAST IRRADIATION WITH HYPOFRACTIONATION PLUS CONCURRENT BOOST VERSUS STANDARD WHOLE BREAST IRRADIATION PLUS SEQUENTIAL BOOST FOR EARLY-STAGE BREAST CANCER |
| RTOG-1012 | Terence Williams | Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer |
| RTOG-1112 | Terence Williams | Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma |
| OSU-09108 | Jennifer Woyach | A Phase I Feasibility/Phase II Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL) |
| OSU-11131 | Christina Wu | A Phase II Study of Panitumumab in Combination with FOLFIRI after Progression on FOLFIRI Plus Bevacizumab in KRAS Wild Type Metastatic Colorectal Cancer. |
| RTOG-1010 | Evan Wuthrick | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-overexpressing Esophageal Adenocarcinoma |
| OSU-12054 | Evan Wuthrick | A phase I trial of MEK inhibitor GSK1120212 in combination with neoadjuvant 5-Fluorouracil chemoradiation in the treatment of KRAS, BRAF, and NRAS-mutant rectal cancers |